首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1290355

全球特发性肺纤维化市场 - 2023-2030年

Global Idiopathic Pulmonary Fibrosis Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球特发性肺纤维化市场规模在2022年达到21.844亿美元，预计到2030年将见证有利可图的增长，达到46.143亿美元。在预测期内（2023-2030年），全球特发性肺纤维化市场预计将呈现10.1%的复合增长率。关键的市场趋势是对强大的管线药物的需求不断增加。

例如，2022年3月，Blade Therapeutics公司宣布了cudetaxestat的差异化特征，这是一种正在临床开发的非竞争性自体细胞素抑制剂，用于治疗IPF和其他纤维化疾病。Cudetaxestat已被授予治疗IPF和系统性硬化症的孤儿药称号。

特发性肺纤维化（IPF）是一种原因不明的慢性进行性疾病，以肺实质的瘢痕化为特征。它是一种与年龄有关的疾病，IPF的纤维化机制仍然难以捉摸，人们赞成的疾病发病机制的概念涉及对遗传上易感的肺泡上皮的反复微损伤，然后是以过度胶原沉积为特征的异常修复反应。

全球特发性肺纤维化市场的驱动因素包括：IPF药物临床试验的增加、老龄化人口的增加、获批疗法的可用性、不断增长的管线和研究性药物、意识的提高和早期诊断，以及研究技术的进步。

例如，2023年5月，全球生物制药公司百时美施贵宝宣布了一项评估BMS-986278的2期研究结果，这是一种潜在的第一类口服溶血磷脂酸受体1（LPA1）拮抗剂，用于特发性肺纤维化患者。该研究表明，与安慰剂相比，每天两次服用60毫克的BMS-986278，持续26周，可使预测强制生命力百分比（ppFVC）的下降率降低62%。

市场动态

获批疗法的可用性

在预测期内，获批疗法的可用性是推动市场份额的主要因素。已获批准的IPF疗法，如吡非尼酮和宁达尼布，已被证明可以减缓疾病的发展，保护肺功能，并减少急性恶化。这些药物针对肺部潜在的纤维化过程，提供了一种改变疾病的方法。这些疗法的出现彻底改变了IPF的管理，使医疗保健提供者能够提供更有效和有针对性的治疗策略。

例如，2022年7月，PureTech公司启动了一项临床研究，评估其实验性疗法LYT-100对特发性肺纤维化（IPF）患者的安全性和有效性。LYT-100中的活性剂被称为deupirfenidone，是Genentech公司销售的已批准的IPF治疗方法Esbriet（吡非尼酮）的化学改性版本。

有限的治疗选择和治疗的副作用

虽然有获批准的IPF治疗方法，但可供选择的治疗方法的数量仍然有限。吡非尼酮和宁达尼布是治疗的主要手段，但一些患者可能没有充分的反应，或可能出现无法忍受的副作用。由于患者和医疗服务提供者寻求更多样化和有效的治疗方法，缺乏替代性治疗方案阻碍了市场的增长。

现有的IPF治疗方法，如吡非尼酮和宁达尼布，都有副作用，对一些患者来说是个挑战。这些副作用可能包括胃肠道症状、肝脏异常、皮疹和其他。副作用的存在可能导致治疗中止或不愿意开始治疗，这可能限制市场增长。

COVID-19影响分析

COVID-19大流行对医疗保健行业，包括特发性肺纤维化市场产生了深远的影响。现有的IPF治疗方法，如吡非尼酮和宁达尼布，都有副作用，对一些病人来说是个挑战。这些副作用可能包括胃肠道症状、肝脏异常、皮疹和其他。副作用的存在可能导致治疗中止或不愿意开始治疗，这可能限制市场增长。

IPF治疗方法和疗法的临床试验也受到大流行病的影响。由于安全问题、资源有限和病人招募困难，许多试验被暂时停止或推迟。临床试验的中断减缓了潜在的新疗法的进展，并延长了其发展的时间。

俄乌冲突分析

俄乌冲突对特发性肺纤维化市场产生了重大影响。冲突及其后果会给医疗基础设施和研究能力带来压力。资源的转移、基础设施的破坏和人才的流失会阻碍研究和开发、临床试验以及获得IPF专业护理的能力。这可能会延缓IPF治疗方案的进步，并限制尖端疗法的可用性。

冲突及其后果会转移对像IPF这样的慢性病的注意力和资源。在危机时期，医疗保健系统往往优先考虑眼前的健康需求、应急反应和急性护理服务。这种焦点的转移可能会导致对像IPF这样的慢性疾病的管理和研究的关注减少。

Market Overview

The Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030). The key market trend is the increasing demand for strong pipeline drugs.

For instance, in March 2022, Blade Therapeutics announced the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause characterized by scarring of the lung parenchyma. It is an age-related disorder and the mechanisms of fibrosis in IPF remain elusive, with favored concepts of disease pathogenesis involving recurrent micro-injuries to a genetically predisposed alveolar epithelium followed by an aberrant reparative response characterized by excessive collagen deposition.

The global idiopathic pulmonary fibrosis market is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the growing pipeline and investigational drugs, rising awareness & early diagnosis, and advancements in research techniques.

For instance, in May 2023, Bristol Myers Squibb, a global biopharmaceutical company announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis. The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 62% compared to placebo.

Market Dynamics

Availability of Approved Therapies

The availability of approved therapies is the major factor driving the market share during the forecast period. Approved IPF therapies, such as pirfenidone and nintedanib, have been shown to slow disease progression, preserve lung function, and reduce acute exacerbations. These medications target the underlying fibrotic processes in the lungs, providing a disease-modifying approach. The availability of these therapies has revolutionized IPF management, allowing healthcare providers to offer more effective and targeted treatment strategies.

For instance, in July 2022, PureTech initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). The active agent in LYT-100, called deupirfenidone, is a chemically-modified version of the approved IPF treatment Esbriet (pirfenidone) marketed by Genentech.

Limited Treatment Options and Side Effects of the Treatment

While there are approved therapies for IPF, the number of available treatment options remains limited. Pirfenidone and nintedanib are the mainstays of treatment, but some patients may not respond adequately or may experience intolerable side effects. The lack of alternative treatment options hampers market growth as patients and healthcare providers seek more diverse and effective therapies.

The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the idiopathic pulmonary fibrosis market. The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

Clinical trials for IPF treatments and therapies were also affected by the pandemic. Many trials were temporarily halted or delayed due to safety concerns, limited resources, and difficulties in patient recruitment. The disruption in clinical trials slowed down the progress of potential new treatments and extended the timeline for their development.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the idiopathic pulmonary fibrosis market. The conflict and its aftermath can strain the healthcare infrastructure and research capabilities. Diverted resources, destruction of infrastructure, and brain drain could hinder the capacity for research and development, clinical trials, and access to specialized IPF care. This can slow down advancements in IPF treatment options and limit the availability of cutting-edge therapies.

The conflict and its consequences can divert attention and resources away from chronic diseases like IPF. In times of crisis, healthcare systems often prioritize immediate health needs, emergency response, and acute care services. This shift in focus may result in reduced attention to the management and research of chronic conditions like IPF.

Segment Analysis

The global idiopathic pulmonary fibrosis market is segmented based on treatment, end-user, and region.

Based on Treatment, the Drugs Segment is Expected to Dominate the Market Share

The market for drugs segment held 45.3% of the global idiopathic pulmonary fibrosis market share in 2022. The drugs segment continues to see significant research and development activities. Pharmaceutical companies are investing in the development of novel drug candidates that target different aspects of IPF pathophysiology. This ongoing innovation in drug development further strengthens the prominence of the drugs segment in the IPF market.

For instance, in October 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced that the first U.S. patient enrolled in FIBRONEER IPF drug, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).

Geographical Analysis

North America Holds the Largest Market Share Due to the High Disease Burden and Availability of Approved Therapies

North America held 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America, particularly the United States, has a high prevalence of IPF compared to other regions. The region's aging population, environmental factors, and lifestyle contribute to the higher disease burden. The significant number of IPF patients in North America drives the demand for IPF treatments and contributes to the region's market dominance.

North America has been at the forefront of research and development in IPF treatment. The region has witnessed early approvals of key therapies for IPF, including pirfenidone and nintedanib. The availability of these approved therapies in North America has significantly contributed to the market growth, as patients have access to effective treatment options.

Competitive Landscape

The major global players in the market include: Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.

Why Purchase the Report?

To visualize the global idiopathic pulmonary fibrosis market segmentation based on treatment, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of idiopathic pulmonary fibrosis market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global idiopathic pulmonary fibrosis market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Treatment
3.2. Snippet by End-User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Availability of Approved Therapies
  - 4.1.1.2. Rising Aging Population
- 4.1.2. Restraints
  - 4.1.2.1. Limited Treatment Options
  - 4.1.2.2. Side Effects of the Treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Advancements in Research Techniques and Treatment Procedures
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Treatment

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 7.1.2. Market Attractiveness Index, By Treatment
7.2. Drugs*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Nintedanib
- 7.2.4. Pirfenidone
7.3. Oxygen Therapy
7.4. Pulmonary Rehabilitation
7.5. Lung Transplant
7.6. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinics
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The UK
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Roche Holdings AG*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Boehringer Ingelheim GmbH
11.3. Genentech Inc.
11.4. FibroGen Inc.
11.5. Galapagos NV
11.6. MEDICINOVA INC.
11.7. Bristol Myers Squibb Company
11.8. Biogen Inc.
11.9. AstraZeneca PLC
11.10. Novartis International AG.

LIST NOT EXHAUSTIVE